Bringhen, Sara
Mina, Roberto
Cafro, Anna Maria
Liberati, Anna Marina
Spada, Stefano
Belotti, Angelo
Gaidano, Gianluca
Patriarca, Francesca
Troia, Rossella
Fanin, Renato
De Paoli, Lorenzo
Rossi, Giuseppe
Lombardo, Alessandra
Bertazzoni, Paola
Palumbo, Antonio
Sonneveld, Pieter
Boccadoro, Mario
Article History
Received: 7 November 2017
Revised: 21 November 2017
Accepted: 22 December 2017
First Online: 30 January 2018
Compliance with ethical standards
:
: S.B. has received honoraria from Celgene, Janssen, BMS, Amgen; Advisory board for Janssen and Amgen; consultancy fees from Takeda; G.G. has served on the advisory boards for Roche, AbbVie, Janssen, Gilead, and Morphosys; F.P. has received lecturing fees from MSD Italia and served on the advisory board for Janssen; L.D.P. has served on the advisory boards for AbbVie, Amgen, Celgene, and Janssen; G.R. has served on the advisory boards for Celgene and Amgen; A.P. is currently a Takeda employee; P.S. has received research support from Amgen, Celgene, Janssen, Karyopharm, and honoraria from Amgen, Celgene, Janssen, Karyopharm and BMS; and M.B. has received research funding from Amgen, BMS, Celgene, Janssen, Mundipharma, Novartis, Sanofi, and honoraria from AbbVie, Amgen, BMS, Celgene, Janssen, Novartis, Sanofi. The remaining authors declare that they have no conflict of interest.